Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | PPIA | P62937 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | PPIF | P30405 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007479 | 0.94 | PPIA (0.43) | KMT2AMEN1MAPTDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL10946501 | 0.92 | ALDH1A1 (0.41) | KMT2AMEN1MAPTDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL7768946 | 0.90 | DPP8 (0.38) | KMT2AMEN1MAPTDPP8DPP9 | |
| SCHEMBL11016662 | 0.87 | PPIA (0.42) | KMT2AMEN1MAPTDPP8DPP9 | |
| SCHEMBL5052635 | 0.86 | PPIA (0.42) | KMT2AMEN1MAPTDPP8DPP9 | |
| SCHEMBL8006884 | 0.86 | ALDH1A1 (0.37) | KMT2AMEN1MAPTDPP8DPP9 | |
| SCHEMBL7130463 | 0.85 | LTA4H (0.39) | MAPTDPP8LTA4HALDH1A1ANPEP | |
| Acetic Acid SCHEMBL9450665 | 0.85 | ALDH1A1 (0.36) | KMT2AMEN1MAPTDPP8DPP9 | |
| SCHEMBL8995288 | 0.84 | SSTR3 (0.46) | SSTR3 | |
| Acetic Acid SCHEMBL179930 | 0.83 | LTA4H (0.36) | DPP8DPP9PPIALTA4HSSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008048288-A2 | NOVEL NANOPARTICLES AND USE THEREOF | MONTANA STATE UNIVERSITY (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20070258889-A1 | NOVEL NANOPARTICLES AND USE THEREOF | MONTANA STATE UNIVERSITY (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1613351-A1 | TARGETED AGENTS FOR BOTH PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY | MPA Technologies, Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1558137-A2 | FUNCTIONAL MRI AGENTS FOR CANCER IMAGING | Research Corporation Technologies (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040247527-A1 | Multifunctional photodynamic agents for treating of disease | MPA TECHNOLOGIES, INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004080483-A1 | TARGETED AGENTS FOR BOTH PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY | MPA TECHNOLOGIES, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040146463-A1 | Functional MRI agents for cancer imaging | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-29 | — | — | US | disclosed |
| WO-2004037210-A2 | FUNCTIONAL MRI AGENTS FOR CANCER IMAGING | RESEARCH CORPORATION TECHNOLOGIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-6673333-B1 | COMPRISING A FIRST GD(III) ION BOUND TO A FIRST CHELATOR; GD(III) ION HAS COORDINATION ATOMS IN AT LEAST 7 COORDINATION SITES; BOUND TO TUMOR ASSOCIATED ACTIVATIVLE GUARDING MOIETY | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030021750-A1 | Novel functional agents for magnetic resonance imaging | METAPROBE, INC. | 2003-01-30 | — | — | US | disclosed |
| EP-1278552-A2 | FUNCTIONAL MRI AGENTS FOR CANCER IMAGING | RESEARCH CORPORATION TECHNOLOGIES (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002080757-A2 | NOVEL FUNCTIONAL AGENTS FOR MAGNETIC RESONANCE IMAGING | METAPROBE, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001082976-A2 | FUNCTIONAL MRI AGENTS FOR CANCER IMAGING | RESEARCH CORPORATION TECHNOLOGIES (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258889-A1 | NOVEL NANOPARTICLES AND USE THEREOF | EEA1, RAB5IF, CD47 | KMT2A 4431/4885MEN1 2550/4885MAPT 828/4885 |
| US-20030021750-A1 | Novel functional agents for magnetic resonance imaging | FABP7, RXFP1, MRGPRX2 | KMT2A 4062/4885MEN1 1233/4885MAPT 3288/4885 |
| US-20040146463-A1 | Functional MRI agents for cancer imaging | TSG101, SMARCE1, SMARCA1 | KMT2A 847/4885MEN1 61/4885MAPT 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.